2019年2月27日 · Cambridge, Massachusetts, February 27, 2019 – Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted …

More than 1 in 4 people worldwide die from arterial thromboembolic events (ischemic heart disease or stroke). Anthos Therapeutics is highly committed to addressing this and other areas …

2023年11月28日 · Anthos Therapeutics was founded by Blackstone Life Sciences in 2019 and obtained from Novartis Pharma AG the exclusive global rights to develop, manufacture, and commercialize abelacimab, a promising novel therapy being developed for patients at …

Anthos Therapeutics is a transformative, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic options for the treatment of cardiovascular metabolic diseases, founded by Blackstone Life Sciences (BXLS).

2024年8月15日 · Anthos Therapeutics was launched by Blackstone Life Sciences and Novartis in 2019 and has obtained the global rights to develop, manufacture, and commercialize abelacimab (MAA868) under a license agreement with Novartis.

2023年9月18日 · Since then, Anthos, the biotech Blackstone created to advance the candidate, has generated evidence that Novartis may have let go of a winner. Anthos linked the antibody to an 80% reduction in...

2019年2月27日 · Blackstone Life Sciences, a private investment firm, along with Novartis, launched Anthos Therapeutics with a $250 million investment. Anthos will be headquartered in Cambridge, Mass.

2019年2月27日 · Blackstone Life Sciences has committed $250 million to create a cardiovascular startup with Novartis. The biotech, Anthos Therapeutics, begins life with an anti-factor XI (FXI) antibody that...

2019年2月28日 · Novartis and private investment platform Blackstone Life Sciences have launched a new biopharmaceutical company Anthos Therapeutics focused on targeted therapies for cardiovascular diseases. Based in the US, the new company will develop and commercialise genetically and pharmacologically validated treatments for high-risk cardiovascular patients.

As part of this launch, Novartis has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. A large unmet medical need exists for next-generation anti-thrombotic therapies in patients currently underserved by conventional anti-coagulant therapies.